Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

TSX:ATE - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Upcoming Discussion ...
View:
Post by MrMugsy on Jan 14, 2024 12:27pm

Upcoming Discussion ...

January 18th ...

Learn about the benefits of otenaproxesul’s new formulation, dive into Antibe’s recently released data and Phase II planning, and explore the future of pain management.

--------------

The future of pain management ... that's likely going to require some reading-between-the-lines.
Comment by Benedictus on Jan 15, 2024 11:48pm
I recall Dan saying a long while back that partnering opportunities for acute would be easier than chronic. Do you agree with that or is that just Dan speak in the same vein as his AME debacle "just a bump in the road"?   It would be really helpful to gain better understanding around partnering potential in a post p2 success scenario as the p3 funding gap looms quite large in my ...more  
Comment by MrMugsy on Jan 16, 2024 9:11am
Regardless of easier or harder - both acute and chronic are huge markets on their own.  Also, acute is a short window for painkiller usage which makes OTENA a perfect candidate.  Chronic is more complex in regimen design w.r.t. the liver (IMO) and success in chronic will come from success in acute ... first. Remember - as far as I'm concerned ... I'll take a chronic flare-up ...more  
Antibe Therapeutics Inc(Pre-Merger)